Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) announced that on November 4, 2026, the company signed an “Exclusive License Agreement” with Evommune, Inc. (“Evommune”) and its wholly-owned subsidiary EvmuneMGD, LLC (“Evommune MGD”), to license the company's VAV1 molecular rubber degrader HP570 (“HP570”) with independent intellectual property rights to Evommune MGD for a fee. Evommune MGD will obtain exclusive rights to develop, manufacture and commercialize HP570 on a global scale (“License Scope”) other than Greater China (including mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). As part of the consideration for the external licensing transaction, the company and its wholly-owned subsidiary Hinova Pharmaceuticals (HK) Limited (“Haichuang Hong Kong”) will now obtain a total of $30 million in non-refundable and non-deductible down payments, including $20 million in cash and $10 million worth of warrants issued by Evommune; at the same time, the company has the right to collect potential development, registration and commercialization milestone payments of up to US$1.07 billion, and corresponding to the net sales volume of products within the licensing area Tiered royalties.

Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) announced that on November 4, 2026, the company signed an “Exclusive License Agreement” with Evommune, Inc. (“Evommune”) and its wholly-owned subsidiary EvmuneMGD, LLC (“Evommune MGD”), to license the company's VAV1 molecular rubber degrader HP570 (“HP570”) with independent intellectual property rights to Evommune MGD for a fee. Evommune MGD will obtain exclusive rights to develop, manufacture and commercialize HP570 on a global scale (“License Scope”) other than Greater China (including mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). As part of the consideration for the external licensing transaction, the company and its wholly-owned subsidiary Hinova Pharmaceuticals (HK) Limited (“Haichuang Hong Kong”) will now obtain a total of $30 million in non-refundable and non-deductible down payments, including $20 million in cash and $10 million worth of warrants issued by Evommune; at the same time, the company has the right to collect potential development, registration and commercialization milestone payments of up to US$1.07 billion, and corresponding to the net sales volume of products within the licensing area Tiered royalties.